



Cancer Program Report 2014





Queen of the Valley Hospital

St Joseph Health

Queen of the Valley Hospital - 2014 Site Table


Site Group	Total Cases	Class		Sex		Stage 0	Stage I	Stage II	Stage III	Stage IV	Unknown
		Analytic	NonAn	M	F						
ALL SITES	661	494	167	323	338	36	117	96	64	97	24
LIP	2	0	2	2	0	0	0	0	0	0	0
TONGUE	14	12	2	11	3	0	2	0	1	7	2
SALIVARY GLANDS, MAJOR	1	0	1	1	0	0	0	0	0	0	0
GUM	1	1	0	0	1	0	0	0	0	1	0
FLOOR OF MOUTH	1	0	1	1	0	0	0	0	0	0	0
TONSIL	4	3	1	4	0	0	0	0	1	1	1
OROPHARYNX	1	1	0	0	1	0	0	1	0	0	0
NASOPHARYNX	3	3	0	1	2	0	0	0	1	2	0
HYPOPHARYNX	2	2	0	2	0	0	0	0	0	2	0
ESOPHAGUS	10	7	3	7	3	0	1	3	2	0	1
STOMACH	5	4	1	4	1	0	1	0	1	2	0
SMALL INTESTINE	1	0	1	1	0	0	0	0	0	0	0
COLON	24	21	3	18	6	0	4	8	3	5	1
RECTUM & RECTOSIGMOID	15	10	5	9	6	0	3	1	3	3	0
ANUS,ANAL CANAL,ANORECTUM	4	1	3	1	3	0	0	0	1	0	0
LIVER	12	9	3	5	7	0	3	2	0	1	2
GALLBLADDER	2	2	0	0	2	1	0	0	0	1	0
BILE DUCTS	2	2	0	1	1	0	0	0	0	1	1
PANCREAS	21	16	5	11	10	1	3	1	0	8	3
RETROPERITONEUM	1	1	0	0	1	0	0	1	0	0	0
PERITONEUM,OMENTUM,MESENT	2	1	1	0	2	0	0	0	1	0	0
LARYNX	6	6	0	6	0	0	2	0	1	3	0
LUNG/BRONCHUS-SMALL CELL	11	10	1	8	3	0	1	1	3	5	0
LUNG/BRONCHUS-NON SM CELL	74	59	15	34	40	3	17	3	13	21	1
HEMERETIC	21	8	13	12	9	0	0	0	0	0	0
MYELOMA	10	5	5	5	5	0	0	0	0	0	0
OTHER HEMATOPOIETIC	6	0	6	2	4	0	0	0	0	0	0
BONE	1	0	1	1	0	0	0	0	0	0	0
SOFT TISSUE	7	6	1	5	2	0	0	1	4	1	0
MELANOMA OF SKIN	10	4	6	6	4	1	0	1	0	1	1
OTHER SKIN CA	3	2	1	2	1	0	1	0	0	0	0
BREAST	137	121	16	0	137	23	45	32	16	3	2
CERVIX UTERI	3	2	1	0	3	0	0	0	1	1	0
CORPUS UTERI	8	4	4	0	8	0	2	1	0	0	1
UTERUS NOS	1	1	0	0	1	0	0	0	0	1	0
OVARY	9	7	2	0	9	0	2	1	1	2	1
VULVA	2	1	1	0	2	0	0	0	1	0	0
OTHER FEMALE GENITAL	1	1	0	0	1	0	0	0	1	0	0
PROSTATE	69	42	27	69	0	0	6	29	2	4	1
TESTIS	4	3	1	4	0	0	1	1	1	0	0
BLADDER	24	17	7	20	4	7	4	2	2	2	0
KIDNEY AND RENAL PELVIS	18	17	1	11	7	0	11	2	0	3	1
URETER	2	2	0	1	1	0	1	1	0	0	0
BRAIN	22	18	4	11	11	0	0	0	0	0	0
OTHER NERVOUS SYSTEM	10	8	2	3	7	0	0	0	0	0	0
THYROID	14	10	4	4	10	0	3	1	2	3	1
OTHER ENDOCRINE	3	2	1	2	1	0	0	0	0	0	0
HODGKIN'S DISEASE	5	3	2	5	0	0	1	1	0	1	0
NON-HODGKIN'S LYMPHOMA	33	23	10	19	14	0	3	2	2	12	4
UNKNOWN OR ILL-DEFINED	19	16	3		5	0	0	0	0	0	0

Queen of the Valley Medical Center 2014 Overview




Male 49%
Female 51%

Analytic 75%
Non-Analytic 25%



Analytic = Cases diagnosed and/or treated at Queen of the Valley
Non-Analytic = Cases diagnosed and treated elsewhere but with active disease at Queen of the Valley



Standard 4.6: 2014 Assessment of Evaluation and Treatment Planning

Breast Cancer – Stage IIA, IIB, and Stage IIIA (T3,N1,M0)

STUDY PURPOSE: To assess the diagnostic work-up and treatment for Stage IIA-B and Stage IIIA breast cancer patients diagnosed and treated at QVMC compared to the NCCN Preoperative Systemic Therapy Guideline.

CoC Cancer Program Requirement: Standard 4.6: Assessment of Evaluation of Treatment Planning: Each year, a physician member of the cancer committee performs a study to assess whether patients within the program are evaluated and treated according to evidence-based national treatment guidelines. The study must determine that the diagnostic evaluation is adequate and the treatment plan is concordant with a recognized guideline.

Physician Member of Cancer Committee to perform study:

STUDY CRITERIA:

Site Specific Sample: Breast Cancer

2012 Cancer Registry Cases, Class of Case 10-14 (Diagnosed and Treated at QVMC). Total cases to be reviewed: = 24 cases

Stage IIA (T2,N0,M0)- 13 cases; Stage IIB (T2,N1,M0, T3,N0,M0)- 6 cases; Stage IIIA (T3,N1,M0)- 5 cases

Analysis: Data reviewed for each case included looking at age, co-morbidities, diagnostic work-up, clinical TNM staging elements and first course of treatment documented in the Cancer Registry abstract. Additionally the EMR and Medical Oncology medical record was reviewed for additional information on treatment and genetic testing/counseling.

Evidence-based national treatment guidelines to be utilized:

NCCN (National Comprehensive Cancer Network) Guidelines Version 2.2012: Breast Cancer

NCCN workup for invasive cancer:

- History and physical exam (PE: at least breast and axillary lymph nodes findings are documented in EMR)
- CBC, platelets
- Liver function tests and alkaline phosphatase
- Diagnostic bilateral mammogram, ultrasound as necessary
- Pathology review following CAP guidelines (core biopsy of breast tumor, clinically + axillary LNs)
- Determination of tumor estrogen/progesterone receptor (ER/PR) status and HER2 status
- Genetic counseling if patient is high risk for hereditary breast cancer
- Breast MRI (optional)
- Consider fertility counseling if indicated
- Consider additional systemic studies only if directed by signs or symptoms: Chest diagnostic CT, Abdominal +/- pelvic diagnostic CT or MRI, Bone scan or sodium fluoride PET/CT, FDG PET/CT

Additional data to collect:

- Age
- Co- morbidities
- Family History of Breast Cancer
- Second breast primaries

First Course of Treatment:

This study will focus on assessing whether preoperative chemotherapy was considered for these women with clinical stage IIA, stage IIB, and stage IIIA tumors who met the criteria for breast-conserving therapy except for tumor size and who wished to undergo breast-conserving therapy.

Treatment analysis will look at:

- Fulfills criteria for breast conserving therapy
- Fulfills criteria for breast conserving therapy except for tumor size:
 - Was preoperative chemotherapy considered/given
- Lumpectomy with surgical axillary staging
- Total mastectomy with surgical axillary staging

ASSESSMENT SUMMARY/FINDINGS: Findings to be presented to Cancer Committee November 4, 2014

QVMC Breast Cancer: 2012 Cancer Registry Cases, Class of Case 10-14 (Diagnosed and Treated at QVMC).

Total cases reviewed: = 24 cases

Stage IIA (T2,N0,M0)- 13 cases; Stage IIB (T2,N1,M0, T3,N0,M0)- 6 cases; Stage IIIA (T3,N1,M0)- 5 cases

DIAGNOSTIC WORKUP SUMMARY:

NCCN (National Comprehensive Cancer Network) Guidelines Version 2.2012: Breast Cancer

Diagnostic Workup	Number	Percentage
History & Physical		
Breast and Axillary LN's	24	100%
+ Family History of Breast Cancer	10	42%
Second Breast Primary	4	17%
Blood workup: CBC/Platelets/LFT/Alk Pos	Not assessed	
Mammogram, Bilateral	19	79%
Mammogram, Unilateral	4	17%
Ultrasound	24	100%
Breast MRI	20	83%
Additional Studies		
PET	4	17%
Pathology		
Ductal	22	92%
Lobular	2	8%
ER/PR/Her2neu performed	24	100%
Diagnostic Approach		
US guided FNA	23	96%
Excisional Bx	1	4%
Genetic testing/counseling referral		
Eligible cases: o Family History of Breast Cancer (10 cases) o Early-age-onset (≤ 50 years) (5 cases) o Two breast primaries in a single person, > age 50 years (4 cases) o Triple Negative (ER-, PR-, Her2-) (1 case) (NCCN Practice Guidelines Criteria for High Risk for Further Risk Evaluation)	17	
Cases referred for genetic testing	8	47%

QVMC Breast Cancer: 2012 Cancer Registry Cases, Class of Case 10-14 (Diagnosed and Treated at QVMC).

Total cases reviewed: = 24 cases

Stage IIA (T2,N0,M0)- 13 cases; Stage IIB (T2,N1,M0, T3,N0,M0)- 6 cases; Stage IIIA (T3,N1,M0)- 5 cases

TREATMENT SUMMARY:

NCCN (National Comprehensive Cancer Network) Guidelines Version 2.2012: Breast Cancer

First Course of Treatment - 24 total cases	Number	Percentage
Surgical Treatment		
Breast Conserving Surgery (BCS)	17	71%
Mastectomy	4	17%
Unknown	2	8%
Refused all treatment	1	4%
Radiation Therapy for BCS (17 applicable cases)		
Radiation Therapy given	13	76%
Radiation Therapy recommended, unknown if given. Not given at QVMC	2	12%
Radiation Therapy recommended, patient refused	2	12%
Considered Not-Applicable:		
Cases having a mastectomy	4	
No treatment or treatment not at QVMC	3	
Radiation Therapy for + Axillary LN (16 applicable cases)		
XRT given	11	69%
Recommended but not given at QVMC	1	6%
Recommended but pt refused	1	6%
XRT not given or unknown if recommended or given	3	19%
Considered Not-Applicable:		
Cases with no positive LNs	5	
No treatment or treatment not at QVMC	3	
Systemic Therapy (19 applicable cases)		
Systemic Therapy before Surgery	7	37%
Systemic Therapy after Surgery	10	53%
Chemo not given: refused	2	11%
Considered Not-Applicable:		
Chemo not given, both Stage IIA: 1 case: HT given, Age 64, No mention of Oncotype study 1 case: HT given, Age 65, Oncotype = low risk score	2	
No treatment or treatment not at QVMC	3	
Systemic Therapy with Herceptin (9 applicable cases that were Her2neu +)		
Herceptin given	7	78%
Herceptin recommended, pt refused	2	22%
Hormone Therapy (18 applicable cases)		
HT given	16	89%
Recommended but refused HT	1	6%
Refused all treatment	1	6%
Considered Not-Applicable:		
ER/PR negative	4	
No treatment or treatment not at QVMC	3	